About the Authors

Gavin J. Churchyard

gchurchyard@auruminstitute.org

Affiliations Aurum Institute, Parktown, South Africa, University of Witwatersrand, School of Public Health, Johannesburg, South Africa, London School of Hygiene and Tropical Medicine, London, United Kingdom

Sue Swindells

Affiliation University of Nebraska Medical Center, Omaha, Nebraska, United States of America

Competing Interests

I have read the journal's policy and the authors of this manuscript have the following competing interests: GJC is the PI on the following trials, which have or will receive drug donations: Sanofi donated isoniazid and rifapentine for the WHIP3TB trial to the Aurum Institute, a not for profit-public-benefit organisation, which is evaluating 3HP given once or annually in high burden countries, funded by USAID; Sanofi donated isoniazid and rifapentine for the Dolphin trial to the Aurum Institute, which is evaluating the safety & PK of 3HP with DTG, which is funded by Unitaid; Otsuka have agreed to donate delamanid for the PHOENIx trial to DAIDS/NIH, which will evaluate delamanid vs INH for treating presumed MDR TB infection among MDR TB exposed MDR TB contacts, which is funded by DAIDS. Johnson and Johnson provided a grant to the Aurum Institute for GJC to attend a Global Health Forum meeting. GJC attended a Sanofi advisory board meeting on 3HP vs 1HP for which payment to himself or the Aurum Institute was declined. SS declares research grants to institution from ViiV Healthcare, NIH salary & travel support for TB research related activities, membership of the US DHHS Antiretroviral Therapy Guidelines Panel.